Home / Companies / Arcutis Biotherapeutics, Inc. / 12 Jun 2025
Arcutis Biotherapeutics, Inc.: meeting of 12 Jun 2025
Votes reported on Form N-PX, item by item
311 Form N-PX filers reported votes at the Arcutis Biotherapeutics, Inc. meeting of 12 Jun 2025. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
3 nominees; 43.0% of reported votes for; 80 filers withheld from or voted against at least one nominee.
542 vote records from 111 filers. 64 of the 111 filers that marked the item either way voted against management.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
421 vote records from 308 filers. 124 of the 298 filers that marked the item either way voted against management. 10 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
180 vote records from 110 filers. 1 of the 110 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | For | For |
| BlackRock and iShares | Abstain or withhold * | For | For |
| Fidelity | For | Against * | For |
| State Street and SPDR | Abstain or withhold * | For | For |
| American Century | Abstain or withhold * | Against * | For |
| Franklin Templeton | For | For | For |
| Invesco | Abstain or withhold * | Against * | For |
| Equitable | Abstain or withhold * | For | For |
| Charles Schwab | Abstain or withhold * | For | For |
| Nuveen and TIAA | For | For | For |
| ProShares and ProFunds | Abstain or withhold * | Against * | For |
| John Hancock and Manulife | For | For | For |
| Morgan Stanley, Eaton Vance and Calvert | Abstain or withhold * | Against * | For |
| J.P. Morgan | For | For | For |
| Goldman Sachs | For | For | For |
| PGIM and Prudential | For | For | For |
| Northern Trust and FlexShares | For | For | For |
| SEI | Abstain or withhold * | For | For |
| T. Rowe Price | For | Against * | For |
| Lincoln Financial | Abstain or withhold | For | For |
| Voya | Abstain or withhold * | For | For |
| First Trust | Abstain or withhold * | Against * | For |
| Russell Investments | No report | For | No report |
| Nationwide | Abstain or withhold * | For | For |
| Victory Capital | Abstain or withhold * | Against * | For |
| Brighthouse Funds | Abstain or withhold * | Against * | For |
| Guggenheim and Rydex | Abstain or withhold * | Against * | For |
| Columbia Threadneedle | For | Against * | For |
| BNY Mellon | No report | Against * | No report |
| Principal | For | Against * | For |
| Pacific Life funds | Abstain or withhold * | For | For |
| Global X | Abstain or withhold * | For | For |
| Federated Hermes | For | For | For |
| AllianceBernstein | No report | Against * | No report |
| DWS | Abstain or withhold * | Against * | For |
| Virtus | Abstain or withhold * | Against * | For |
| Neuberger Berman | No report | For | No report |
| Natixis and Loomis Sayles | No report | For | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Arcutis Biotherapeutics, Inc. meeting?
311 Form N-PX filers reported votes at the meeting of 12 Jun 2025. On say-on-pay, 124 of 298 voted against management (41.6%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Arcutis Biotherapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Arcutis Biotherapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Arcutis Biotherapeutics, Inc. with a meeting date within three days of 12 Jun 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.